176 related articles for article (PubMed ID: 11706403)
1. HER2 overexpression and cancer targeting.
Wang SC; Hung MC
Semin Oncol; 2001 Oct; 28(5 Suppl 16):115-24. PubMed ID: 11706403
[TBL] [Abstract][Full Text] [Related]
2. Targeting HER2: recent developments and future directions for breast cancer patients.
Wang SC; Zhang L; Hortobagyi GN; Hung MC
Semin Oncol; 2001 Dec; 28(6 Suppl 18):21-9. PubMed ID: 11774202
[TBL] [Abstract][Full Text] [Related]
3. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
4. The N-terminal domain of SV40 large T antigen represses the HER2/neu-mediated transformation and metastatic potential in breast cancers.
Chuang TC; Yu YH; Lin YS; Wang SS; Kao MC
FEBS Lett; 2002 Jan; 511(1-3):46-50. PubMed ID: 11821047
[TBL] [Abstract][Full Text] [Related]
5. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.
Menendez JA; Vellon L; Mehmi I; Oza BP; Ropero S; Colomer R; Lupu R
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10715-20. PubMed ID: 15235125
[TBL] [Abstract][Full Text] [Related]
7. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation of cellular signaling by HER2/neu in breast cancer.
Zhou BP; Hung MC
Semin Oncol; 2003 Oct; 30(5 Suppl 16):38-48. PubMed ID: 14613025
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
[TBL] [Abstract][Full Text] [Related]
10. E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs.
Zhou Z; Jia SF; Hung MC; Kleinerman ES
Cancer Res; 2001 Apr; 61(8):3394-8. PubMed ID: 11309298
[TBL] [Abstract][Full Text] [Related]
11. The role of the HER-2/neu oncogene in gynecologic cancers.
Cirisano FD; Karlan BY
J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816
[TBL] [Abstract][Full Text] [Related]
12. Towards sustained silencing of HER2/neu in cancer by epigenetic editing.
Falahi F; Huisman C; Kazemier HG; van der Vlies P; Kok K; Hospers GA; Rots MG
Mol Cancer Res; 2013 Sep; 11(9):1029-39. PubMed ID: 23814024
[TBL] [Abstract][Full Text] [Related]
13. [Down regulation of HER2/neu expression by adenovirus E1A and its anti-tumor activity].
Lu H; Qin H; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2000 Sep; 22(5):370-3. PubMed ID: 11778270
[TBL] [Abstract][Full Text] [Related]
14. Human manganese superoxide dismutase suppresses HER2/neu-mediated breast cancer malignancy.
Chuang TC; Liu JY; Lin CT; Tang YT; Yeh MH; Chang SC; Li JW; Kao MC
FEBS Lett; 2007 Sep; 581(23):4443-9. PubMed ID: 17719580
[TBL] [Abstract][Full Text] [Related]
15. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
[TBL] [Abstract][Full Text] [Related]
16. HER2/neu antisense targeting of human breast carcinoma.
Roh H; Pippin JA; Green DW; Boswell CB; Hirose CT; Mokadam N; Drebin JA
Oncogene; 2000 Dec; 19(53):6138-43. PubMed ID: 11156527
[TBL] [Abstract][Full Text] [Related]
17. Structural insights into the down-regulation of overexpressed p185(her2/neu) protein of transformed cells by the antibody chA21.
Zhou H; Zha Z; Liu Y; Zhang H; Zhu J; Hu S; Shen G; Cheng L; Niu L; Greene MI; Teng M; Liu J
J Biol Chem; 2011 Sep; 286(36):31676-83. PubMed ID: 21680730
[TBL] [Abstract][Full Text] [Related]
18. p66Shc isoform down-regulated and not required for HER-2/neu signaling pathway in human breast cancer cell lines with HER-2/neu overexpression.
Xie Y; Hung MC
Biochem Biophys Res Commun; 1996 Apr; 221(1):140-5. PubMed ID: 8660324
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.
Ueno NT; Yu D; Hung MC
Oncogene; 1997 Aug; 15(8):953-60. PubMed ID: 9285690
[TBL] [Abstract][Full Text] [Related]
20. The N-terminal domain of EBNA1 acts as a suppressor of the HER2/neu oncogene.
Liu JY; Chuang TC; Way TD; Tsai TC; Hu CL; Liu GY; Wang SS; Chung JG; Kao MC
Cancer Lett; 2009 Jan; 273(2):273-80. PubMed ID: 18805633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
